Who is BlueOcean?
BlueOcean is an investment firm that has developed multiple funds over the past decade. These funds are tailored towards the MedTech (Medical Technology) industry.
MedTech represents a massive industry in Europe alone, and is quite broad in its description. Those within the industry may be credited with developing next-gen pacemakers, atrial valves, insulin delivery vehicles, and even deep brain stimulation methods.
BlueOcean recognizes not only the importance of this industry, but also the potential to both help and benefit it simultaneously.
What is the problem?
With over 12,000 patents filed within MedTech in 2016, over 40% of these originated from Europe. Furthermore, of the over $1 billion invested every year in Swiss startups, $600 million of this is funneled towards healthcare. From these numbers, it is clear – MedTech is booming.
Unfortunately, due to the vast amount of money and companies entering the industry, it is a difficult process to filter which start-ups are truly promising, and which aren’t. This process requires vast amounts of experience in various fields ranging from Medical to Legal, financial and more.
Another hurdle that must be cleared is the fact that many investment funds are unable to take part in private equity.
With each of these hurdles in place, despite the amount of money flowing into the industry, many of the best opportunities remain either hard to spot, or simply out of reach.
How will they solve it?
BlueOcean Ventures is an investment firm that possesses experts in the following fields.
By having a diverse cast of experts, the firm has a history of selecting successful start-ups. Currently, this team is actively building their second fund. This is known as the BlueOcean Ventures II. This fund currently has holdings in 5 different companies within the MedTech industry. The firm is looking to both expand and increase their holdings in these companies.
To achieve their goal of expansion and increased exposure, BlueOcean is hosting an STO. This STO will allow accredited investors the ability to invest in pre-vetted start-ups. This means that they can take advantage of the wide array of skills the BlueOcean team brings to the table.
By utilizing blockchain technology, the investors in the fund will benefit from not only increased transparency (where are the funds being spent), but also from increased levels of liquidity. As there is no lock-up period on the BlueOcean tokens (BOV), investors will be able to trade their tokens on secondary markets in a short amount of time. Tokens are expected to be listed on cryptocurrency exchanges by Q1 of 2019.
More than just a fund providing capital, the team at BlueOcean provides its portfolio of companies with much more. This may range from providing access to industry experts and hard to make contacts. Below are a few of those leading the way at BlueOcean.
With their STO currently active, BlueOcean will be preparing for token distribution. Once complete, the funds garnered throughout the STO will be able to be put to use, and begin working for the investors that participated. BlueOcean indicates that 100% of these funds will be invested in BlueOcean Ventures II.
For those looking to invest in MedTech start-ups via a curated fund, check out the BlueOcean STO; The easiest way to gain indirect equity in these promising start-ups.
The fund is scheduled to close in 2025. Upon closure, all assets will be proportionately divvied up among remaining investors.
To learn details about the project, please view our BlueOcean Ventures Token Listing page.